Two New Stars in Weight Loss Feild
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk, mainly used to treat type 2 diabetes and obesity. It mimics the effects of GLP-1, enhances insulin secretion, inhibits glucagon release, delays gastric emptying and increases satiety, thereby effectively lowering blood sugar and reducing weight.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company, mainly used to treat type 2 diabetes and obesity. It activates GIP and GLP-1 receptors simultaneously, significantly enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying and increasing satiety, thereby effectively lowering blood sugar and promoting weight loss.
differences between Tirzepatide and Semaglutide
1. Development time
Semaglutide: Developed by Novo Nordisk, it was first approved for type 2 diabetes in 2017 (trade name Ozempic) and approved for obesity in 2021 (Wegovy).
Tirzepatide: Developed by Eli Lilly, it was approved for type 2 diabetes in 2022 (trade name Mounjaro), and the obesity indication was approved in 2023 (Zepbound).
2. Functions and indications
Semaglutide:
Glucose reduction: Promotes insulin secretion and inhibits glucagon through GLP-1 receptor agonism.
Weight loss: By delaying gastric emptying and central appetite suppression, the average weight loss is about 15% (Wegovy clinical trial).
Tirzepatide:
Dual agonist: Targets GLP-1 and GIP receptors at the same time, synergistically enhancing the glucose reduction and weight loss effects.
More effective: In the SURPASS series of trials, the glucose reduction and weight loss effects are better than Semaglutide (average weight loss up to 22.5%).
3. Mechanism of action
Semaglutide:
Single activation of GLP-1 receptor, increasing insulin sensitivity and suppressing appetite.
Tirzepatide:
GLP-1 receptor agonist: Similar to Semaglutide, but with higher intensity.
GIP receptor agonist: Enhances adipose tissue energy consumption and may improve insulin resistance.
4. Safety
Common adverse reactions:
Gastrointestinal reactions (nausea, diarrhea, vomiting) are the most common, and the incidence of Tirzepatide is slightly higher.
Risk of hypoglycemia:
Both are low when used alone, but caution is required when used in combination with insulin or sulfonylureas.
Other risks:
Semaglutide has a black box warning for medullary thyroid carcinoma (MTC) (common to GLP-1 receptor agonists), and Tirzepatide has no additional warnings.
Conclusion
Tirzepatide advantage: dual mechanism, more significant glucose lowering and weight loss effects.
Semaglutide advantage: longer clinical use experience, potentially lower price (depending on the region).
Selection basis: needs to be comprehensively evaluated based on the patient's efficacy needs, tolerability and cost.
